Dasatinib (D) in previously treated metastatic colorectal cancer (mCRC) patients: A phase II trial of the University of Chicago phase II consortium. Background: Patients with NIDDM have an increased ...
Evaluating the relationship between progression-free survival (PFS) and overall survival (OS) in clinical trials of patients (pts) with metastatic colorectal cancer (mCRC). Background: Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback